美容护理行业2025Q1基金持仓分析：25Q1美护基金持仓比例小幅回升，个护、医美处于超配区间

Investment Rating - The report rates the beauty and personal care industry as "outperforming the market" [23] Core Insights - In Q1 2025, the fund allocation ratio for the beauty and personal care industry increased slightly, with a total market capitalization of 254.203 billion yuan, up 3.38% from Q4 2024. The total market value of fund holdings in this sector reached 69.182 billion yuan, resulting in a fund allocation ratio of 0.27%, which is an increase of 0.06 percentage points from the previous quarter [11][12] - The individual segments of personal care and medical beauty are in an overweight position, while the cosmetics segment has reached a record low in underweight allocation [3][15] Summary by Sections Fund Allocation Analysis - The beauty and personal care industry saw a fund allocation ratio of 0.27% in Q1 2025, which is an increase of 0.06 percentage points from Q4 2024. The overweight ratio remains at -0.05%, indicating a continued underweight position [11][21] - The personal care segment's fund allocation ratio was 0.09% in Q1 2025, up 0.02 percentage points, with an overweight ratio of 0.03% [15] - The cosmetics segment's fund allocation ratio fell to 0.04%, with an overweight ratio declining to a historical low of -0.12% [15] - The medical beauty segment's fund allocation ratio was 0.13%, with an overweight ratio of 0.03% [15] Top Holdings - The top three stocks in the beauty and personal care sector by fund holding ratio in Q1 2025 are Aimeike, Jinbo Biological, and Stable Medical [16][17] - The total holding ratio of the top ten stocks in this sector was 0.10%, an increase of 0.02 percentage points from the previous quarter [16] Investment Recommendations - The report suggests focusing on cosmetics and medical beauty, as there is significant demand potential in the medium to long term due to the "beauty economy." Regulatory policies favor compliant leading companies in these sectors [21] - For personal care products, the report highlights the growing consumer emphasis on health and care, recommending attention to leading companies with strong R&D capabilities and diverse product matrices [21]